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Abstract
We recently developed a Janus kinase 2 (Jak2) small-molecule inhibitor called G6 and found that it inhibits Jak2-V617F–
mediated pathologic cell growth in vitro, ex vivo, and in vivo. However, its ability to inhibit Jak2-V617F–mediated myelo-
proliferative neoplasia, with particular emphasis in the bone marrow, has not previously been examined. Here, we investi-
gated the efficacy of G6 in a transgenic mouse model of Jak2-V617F–mediated myeloproliferative neoplasia. We found that
G6 provided therapeutic benefit to the peripheral blood as determined by elimination of leukocytosis, thrombocytosis, and
erythrocytosis. G6 normalized the pathologically high plasma concentrations of interleukin 6 (IL-6). In the liver, G6 eliminated
Jak2-V617F–driven extramedullary hematopoiesis. With respect to the spleen, G6 significantly reduced both the spleno-
megaly andmegakaryocytic hyperplasia. In the critically important bonemarrow, G6 normalized the pathologically high levels
of phospho-Jak2 and phospho–signal transducer and activator of transcription 5 (STAT5). It significantly reduced the mega-
karyocytic hyperplasia in the marrow and completely normalized theM /E ratio. Most importantly, G6 selectively reduced the
mutant Jak2 burden by 67% on average, with virtual elimination of mutant Jak2 cells in one third of all treated mice. Lastly,
clonogenic assays using marrow stem cells from the myeloproliferative neoplasm mice revealed a time-dependent elimina-
tion of the clonogenic growth potential of these cells by G6. Collectively, these data indicate that G6 exhibits exceptional
efficacy in the peripheral blood, liver, spleen, and, most importantly, in the bone marrow, thereby raising the possibility that
this compound may alter the natural history of Jak2-V617F–mediated myeloproliferative neoplasia.
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Introduction
Polycythemia vera (PV), essential thrombocythemia (ET), and primary
myelofibrosis (PMF) are myeloproliferative neoplasms (MPNs) lacking
the Philadelphia chromosome. They are caused by the transformation
of an early hematopoietic stem cell resulting in abnormal hematopoiesis
[1,2]. These disorders are categorized according to the syndromes caused
by the terminally differentiated hematopoietic cells such as increased
production of red blood cells (PV), platelets (ET), and neutrophils with
concomitant fibrosis of the bone marrow tissue (PMF). Clinically, these
diseases are characterized by pathologic peripheral blood syndromes
such as leukocytosis, erythrocytosis, and thrombocytosis. These syn-
dromes predispose patients to vascular diseases such as thrombosis,
atherosclerosis, coronary heart disease, and cerebral ischemia [3–7]. In
addition, patients with MPNs often have high levels of circulating in-
flammatory cytokines, such as interleukin 6 (IL-6), which have been
associated with symptoms such as cachexia and listlessness [8–12].
Moreover, MPNs can often transform to acute myeloid leukemia
[12]. Although these disorders can be fatal with a life expectancy that
can be as few as 5 years [13], currently available treatments are limited.
The discovery of the Janus kinase 2 (Jak2)–V617F mutation in most
patients with MPN spurred the development of small-molecule Jak2
inhibitors through molecularly targeted drug discovery. In preclinical
experiments, many of these small molecules exhibited potent inhibition
of Jak2-mediated pathologic cell growth. Some have subsequently pro-
gressed to clinical trials where they exhibited some benefit by reducing
clinical symptoms associated with the MPN phenotype [14]. However,
none of these inhibitors have been reported to be curative because they
have little to no efficacy in the bone marrow and there is often a relapse
of the clinical disease manifestations after withdrawal of treatment.
Thus, current Jak2 inhibitors are largely palliative because they are un-
able to eradicate the Jak2 mutant burden in the bone marrow, which
is the primary predilection site of the MPN disease pathogenesis.
Recently, we developed a stilbenoid small-molecule Jak2 inhibitor,
G6, which exhibits potent inhibition of Jak2-V617F–mediated path-
ologic cell growth in vitro and ex vivo [15,16]. We subsequently re-
ported that G6 has therapeutic potential in a NOD-SCIDmouse model
of Jak2-V617F–mediated hyperplasia because it eliminated the burden
of tumorigenic Jak2-V617F cells from the host bone marrow [17].
However, its ability to inhibit Jak2-V617F–mediated myeloproliferative
neoplasia, with particular emphasis in the bone marrow, is not known.
Therefore, we hypothesized here that G6 would be efficacious against
Jak2-V617F–mediated myeloproliferative neoplasia and would provide
significant efficacy to a number of tissues including the bone marrow. To
test this, we used a transgenic mouse model of Jak2-V617F–mediated
myeloproliferative neoplasia and found that G6 treatment greatly alle-
viated the phenotype by providing significant therapeutic benefit to the
peripheral blood, liver, spleen, and, most notably, the bone marrow. As
such, G6may alter the natural history of Jak2-V617F–mediated myelo-
proliferative neoplasia, thereby raising the possibility that this com-
pound may have curative potential.
Materials and Methods
Animals
All animal procedures were approved by the Institutional Animal
Care and Use Committee at the University of Florida. Animals were
maintained in accordance with National Institutes of Health standards
established in the Guidelines for the Care and Use of Experimental
Animals. Transgenic male mice expressing the Jak2-V617F mutated
enzyme in the hematopoietic system driven by the vav promoter and
generated on a C57BL/6 background strain were used in these experi-
ments; their creation and characterization have previously been de-
scribed [18]. The transgenic mice were identified by polymerase chain
reaction (PCR) using primers 5′-TACAACCTCAGTGGGACAAA-
GAAGAAC and 5′-CCATGCCAACTGTTTAGCAACTTCA, which
cover a 594-bp region in the coding sequence of Jak2-V617F [18]. At
3 months of age, a baseline peripheral blood sample was obtained from
each mouse through submandibular bleeding. The mice then received
vehicle (n = 6) or 10-mg/kg per day (n = 6) injections of G6 for 28 days.
Blood samples were subsequently obtained after 14 and 28 days of
vehicle or G6 treatment.
Analysis of Peripheral Blood Cells
Blood samples were obtained (∼50 μl) through submandibular
bleeding into tubes containing potassium salt of ethylenediamine tetra-
acetic acid. Complete blood cell (CBC) counts were obtained using a
HESKA Vet ABC-Diff Hematology analyzer (Heska, Loveland, CO).
Blood samples were also smeared onto glass slides and stained using
DipQuick (Jorgensen Laboratories, Inc, Loveland, CO).
IL-6 Analysis
Blood samples were obtained (∼50 μl) through submandibular
bleeding into tubes containing potassium salt of ethylenediamine
tetraacetic acid. Plasma was centrifuged at 10,000g for 10 minutes
and then stored at −80°C for subsequent analysis. Plasma levels of
IL-6 were measured using a commercially available mouse ELISA kit
(Ray Biotech, Norcross, GA) according to themanufacturer’s instructions.
Histologic Analysis
Tissues (liver, spleen, and femurs) were fixed overnight in buffered
formalin. Femurs were decalcified for 16 hours. The tissues were sub-
sequently dehydrated through a graded ethanol series, paraffin embed-
ded, and sectioned (4 μm). The tissues were then stained with
hematoxylin and eosin, and they were examined for normal histologic
appearance as well as any lesions through standard light microscopy by
two independent veterinary pathologists who were blinded to treatment
groups. Bone marrow analysis was done according to established guide-
lines [19]. The bone marrow was evaluated for necrosis, fibrosis, hem-
orrhage, overall cellularity,M/E ratios, and megakaryocytic counts. All
cell counts were made at 600× high-power field (HPF). Spleen sections
were examined for evidence of extramedullary hematopoiesis (EMH),
and a quantitative analysis of megakaryocytes was made. Liver sections
were examined for evidence of EMH at 40×.
Immunohistochemistry
Immunohistochemistry (IHC) on bone marrow samples was carried
out as previously described [17]. Briefly, 5-μm sections mounted on
gelatin-coated slides were dewaxed in ethanol, rehydrated, and then
blocked in 3% H2O2 followed by 5% normal goat serum. Sections were
exposed to either anti–phospho-Jak2 (Ab32101; Abcam, Cambridge,
MA) or anti–phospho-signal transducer and activator of transcription 5
(STAT5, Ab32364; Abcam) primary antibody overnight at 4°C. The
sections were washed and then treated with the biotinylated secondary
antibody. After secondary antibody incubation, the samples were
washed, exposed to the avidin-peroxidase reagent (Vectastain Elite; Vector
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Laboratories, Burlingame, CA), and reacted with diaminobenzidine to
produce a brown reaction product. The sections were dehydrated in
ethanol, mounted with Permount (Fisher Scientific, Pittsburgh, PA),
and observed by light microscopy.
Determination of Jak2-V617F Allele Burden
in the Bone Marrow
RNA was isolated from bone marrow using the RNeasy Mini Kit
(QIAGEN, Valencia, CA), and DNA contamination was removed
using the RNase-free DNase set (QIAGEN). Complementary DNA
(cDNA) was synthesized using the high-capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Carlsbad, CA) from 2 μg of
RNA. Real-time PCR was performed in a Multicolor Real-time PCR
Detection System using TaqMan gene expression assays (Applied
Biosystems). PCR amplifications were performed in duplicate for
human Jak2 (Hs01078124_m1) and mouse Jak2 (Mm00434577_m1)
along with parallel measurements of mouse β-actin cDNA as an internal
control. The copy number of the human Jak2 sequence relative to β-actin
Table 1. Summary of Peripheral Blood Analyses of Nontransgenic and Vehicle- or G6-Treated Jak2-V617F Transgenic Mice.
RBC (M/μl) HCT (%) MCV (f l) RDW (%)
Nontransgenic 9.7 ± 0.1 42.4 ± 0.2 43.7 ± 0.3 18.3 ± 0.5
Jak2-V617F Vehicle G6 Vehicle G6 Vehicle G6 Vehicle G6
Baseline 13.5 ± 0.4 13.7 ± 0.7 53.0 ± 1.3 53.5 ± 1.9 39.3 ± 0.3 39.3 ± 0.5 20.4 ± 0.3 20.5 ± 0.2
Week 2 13.7 ± 0.6 10.7 ± 1.3*,† 52.2 ± 2.0 42.1 ± 4.8*,† 38.3 ± 0.5 39.6 ± 0.9 20.5 ± 0.3 19.5 ± 0.5
Week 4 12.6 ± 0.5 10.3 ± 0.5*,† 47.2 ± 1.4 43.0 ± 0.5† 37.2 ± 0.6 42.2 ± 1.4*,† 20.2 ± 0.4 18.3 ± 0.4*,†
HB (g/dL) MCH (pg) MCHC (g/dL)
Nontransgeinc 11.9 ± 0.1 12.3 ± 0.2 28.1 ± 0.4
Jak2-V617F Vehicle G6 Vehicle G6 Vehicle G6
Baseline 14.3 ± 0.3 14.4 ± 0.6 10.6 ± 0.1 10.6 ± 0.1 27.1 ± 0.2 26.9 ± 0.3
Week 2 15.5 ± 0.7 12.5 ± 1.4* 11.3 ± 0.1 11.8 ± 0.2† 29.8 ± 0.2† 29.8 ± 0.3†
Week 4 13.9 ± 0.4 12.1 ± 0.2 11.1 ± 0.2 11.9 ± 0.4*,† 29.7 ± 0.2 28.2 ± 0.3*,†
PLT (K/μl) MPV (f l) PDW (%)
Nontransgenic 1198 ± 151 4.0 ± 0.4 30.2 ± 0.6
Jak2-V617F Vehicle G6 Vehicle G6 Vehicle G6
Baseline 2879 ± 145 2802 ± 234 5.3 ± 0.1 5.3 ± 0.1 28.7 ± 0.4 28.9 ± 0.4
Week 2 2732 ± 465 1708 ± 259*,† 5.4 ± 0.1 5.0 ± 0.2* 25.9 ± 1.2 28.1 ± 1.5
Week 4 3311 ± 313 1180 ± 253*,† 5.4 ± 0.2 4.1 ± 0.3*,† 27.2 ± 1.4 31.7 ± 1.9*
WBC (K/μl) NE (K/μl) NE (%)
Nontransgenic 9.1 ± 0.9 2.4 ± 0.3 23.4 ± 2.3
Jak2-V617F Vehicle G6 Vehicle G6 Vehicle G6
Baseline 16.8 ± 1.6 14.8 ± 0.9 5.3 ± 0.5 5.8 ± 0.9 34.1 ± 2.6 34.9 ± 2.9
Week 2 19.8 ± 2.4 12.0 ± 3.1* 6.2 ± 0.9 4.3 ± 1.1 31.3 ± 2.2 30.0 ± 2.6
Week 4 21.3 ± 2.6 10.3 ± 0.9* 7.5 ± 1.1 2.7 ± 0.3*,† 35.1 ± 1.1 27.3 ± 3.6
LY (K/μl) LY (%) MO (K/μl) MO (%)
Nontransgenic 6.4 ± 0.7 62.4 ± 1.5 0.8 ± 0.1 7.9 ± 0.9
Jak2-V617F Vehicle G6 Vehicle G6 Vehicle G6 Vehicle G6
Baseline 8.2 ± 0.6 8.1 ± 0.9 51.4 ± 1.8 51.7 ± 3.4 1.7 ± 0.2 1.4 ± 0.2 11.0 ± 1.1 9.2 ± 0.6
Week 2 10.3 ± 1.3 6.7 ± 1.5* 52.1 ± 2.9 57.6 ± 2.8 2.4 ± 0.4 1.3 ± 0.3* 12.2 ± 1.2 9.3 ± 1.1*
Week 4 10.8 ± 1.3 6.1 ± 0.8* 50.7 ± 0.9 59.0 ± 3.8* 2.0 ± 0.3 0.8 ± 0.1* 9.13 ± 0.3 8.0 ± 0.8
EO (K/μl) EO (%) BA (K/μl) BA (%)
Nontransgenic 0.6 ± 0.2 4.7 ± 0.6 0.1 ± 0.0 0.7 ± 0.4
Jak2-V617F Vehicle G6 Vehicle G6 Vehicle G6 Vehicle G6
Baseline 0.6 ± 0.1 0.5 ± 0.1 3.4 ± 0.8 3.9 ± 0.3 0.0 ± 0.0 0.0 ± 0.0 0.1 ± 0.0 0.3 ± 0.1
Week 2 0.8 ± 0.1 0.5 ± 0.2 4.0 ± 0.6 2.6 ± 0.7 0.1 ± 0.0 0.1 ± 0.1 0.5 ± 0.2 0.6 ± 0.1
Week 4 0.9 ± 0.2 0.5 ± 0.1 4.5 ± 1.0 4.7 ± 0.6 0.1 ± 0.0 0.1 ± 0.0 0.6 ± 0.2 0.1 ± 0.0
BA indicates basophil; EO, eosinophil; HB, hemoglobin; HCT, hematocrit; LY, lymphocyte; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean
corpuscular volume; MO, monocyte; MPV, mean platelet volume; NE, neutrophil; PDW, platelet distribution width; PLT, platelet; RBC, red blood cell; RDW, red blood cell distribution width; WBC,
white blood cell.
*P < .05 in reference to vehicle treated.
†P < .05 in reference to baseline.
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was calculated using a standard curve technique. The allele burden was
computed by calculating the ratio of human Jak2-V617F to endogenous
mouse Jak2–wild-type (WT) transcripts.
Clonogenic Assay
Bone marrow cells from Jak2-V617F transgenic mice were harvested
from the femur through aspiration. After 2 days of culture ex vivo, the
cells were exposed to 25 μM of G6 for the indicated periods and then
washed extensively. Duplicate cultures were then plated in MethoCult
medium (STEMCELLTechnologies, Vancouver, Canada) lacking erythro-
poietin and thrombopoietin. Five days later, the number of granulocyte-
macrophage colony-forming units and erythroid burst-forming units were
counted and plotted as a function of treatment condition.
Statistical Analysis
All results were expressed as mean ± SEM. Statistical comparisons were
performed by Student’s t test. Changes in peripheral blood cell counts
were analyzed by a repeated-measures analysis of variance followed by
Bonferroni and Student-Newman-Keuls post hoc test for multiple com-
parisons. P < .05 (2-tailed) were considered statistically significant.
Results
G6 Provides Therapeutic Benefit in the Peripheral Blood
of Jak2-V617F MPN Mice
Here, we used a previously established transgenic mouse model of
Jak2-V617F–mediated myeloproliferative neoplasia [18]. These mice
express the human Jak2-V617F cDNA under the control of the hema-
topoietic promoter, vav. These mice exhibit a number of phenotypes
that recapitulate those observed in human MPN including constitutive
Jak/STAT signaling, myeloid neoplasia, leukocytosis, thrombocytosis,
erythrocytosis, and splenomegaly. CBC counts were first performed on
3-month-old male mice to confirm the MPN phenotype. Mice fully
manifesting the MPN phenotype were randomly assigned to one of two
groups (n = 6 per group) and then began receiving either 10mg/kg per day
of G6 or vehicle control solution. CBCs were subsequently collected on
days 14 and 28 of treatment through mandibular vein bleeding, and after
28 days of treatment, all themice were euthanized and prepared for analysis.
The CBC values were first examined by a repeated-measures analysis
of variance to determine whether there were any significant differences
between treatment conditions (Table 1). Values from nontransgenic
control mice are also shown for comparison. We found that G6 pro-
vided significant therapeutic improvement in the red blood cell count,
Figure 1. G6 provides therapeutic benefit in the peripheral blood of Jak2-V617F MPN mice. (A) Representative peripheral blood smears
from wild-type and Jak2-V617F MPN mice at low (upper panel) and high magnification (lower panel). The giant platelets are indicated by
green arrows. (B) Plasma IL-6 concentrations. *P = 2.62 × 10−6, **P = 6.37 × 10−8.
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hematocrit, mean corpuscular volume, red blood cell distribution width,
hemoglobin, mean corpuscular hemoglobin, mean corpuscular hemoglo-
bin concentration, platelet count, mean platelet volume, platelet distribu-
tion width, white blood cell count, neutrophil count, lymphocyte count,
and monocyte count. To confirm these observations using an alternate
means, terminal peripheral blood smears from all mice were examined
in parallel. In addition to validating many of the CBC values, examina-
tion of the slides revealed an increased appearance of large platelets in
the vehicle-treatedMPNmice that were lacking in the nontransgenic
control mice (WT) and G6-treated mice (Figure 1A).
A previous work has shown that MPN patients have significantly
elevated levels of inflammatory cytokines in the peripheral blood, such
as IL-6 [11]. To determine whether this was also the case in our MPN
mice and whether G6 could correct this, terminal plasma IL-6 concen-
trations from the mice were determined. When compared with non-
transgenic WT controls, we found that the plasma concentrations of
IL-6 were markedly elevated in the vehicle-treated MPNmice, and this
was completely normalized with G6 treatment (Figure 1B).
We next wanted to determine whether the efficacious parameters
observed in the peripheral blood of G6-treated mice correlated with the
presence of the drug in the plasma. For this, mass spectrometry analysis
was performed on the terminal plasma samples and the levels of G6
were determined (Table 2). We found that G6 was detectable in plasma
samples from the mice that received the drug but not in the plasma
taken from mice that received vehicle control solution.
Altogether, the data inTables 1 and 2 aswell as those in Figure 1 indicate
that G6 corrected, or in some cases completely normalized, numerous
Figure 2. G6 reduces EMH in Jak2-V617F MPN mice. (A) Liver sections showing EMH sites at the indicated magnifications (green arrows).
(B) The average number of EMH sites plotted as a function of treatment group.
Table 2. Mass Spectrometry Results Showing Plasma Concentrations of G6 at Euthanasia of
Jak2-V617F Transgenic Mice.
Animal ID Plasma* (μg/ml)
Vehicle Treated
1 <0
2 <0
3 <0
4 <0
5 <0
6 <0
G6 Treated
1 48.6
2 0.155
3 0.036
4 0.025
5 0.030
6 ND
*Standard curve was quadratic (1/x2), r = 0.9902 with range from 0.005 to 5.00 μg/ml. Shown is the
average of replicate injections. Calculations were done using Analyst Software 1.4.2 (AB Sciex, Foster
City, CA). Less than zero (<0) indicates peak quantities below the 0 value of the standard curve. ND
indicates that value was not determined because of insufficient sample quantity at the time of analysis.
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cell compartments within the peripheral blood in a mouse model of
Jak2-V617F–mediated myeloproliferative neoplasia. Furthermore, G6
treatment completely normalized the levels of IL-6 in the plasma of these
mice. Finally, the improvement observed in the G6-treated mice corre-
lated positively with the presence of G6 in the plasma of these animals.
G6 Reduces EMH in Jak2-V617F MPN Mice
Another pathologic finding observed in the Jak2-V617F MPN
mice is an abnormally high degree of EMH. Constitutive expression
of the Jak2-V617F transgene drives hematopoiesis in a number of
tissues including the liver. To determine whether G6 could reduce this
Jak2-V617F–mediated pathogenesis, postmortem liver sections were
examined by light microscopy and the levels of EMH were quantified.
Figure 2A shows representative liver sections from all conditions and
Figure 2B shows the quantitative values of EMH plotted as a function
of condition. We found that when compared to wild-type mice, the
MPN mice treated with vehicle control solution exhibited an increased
level of EMH. However, this was corrected with G6 treatment. Over-
all, the data in Figure 2 indicate that G6 is efficacious in the liver given
its ability to normalize the levels of EMH in Jak2-V617F MPN mice.
G6 Provides Therapeutic Benefit to the Spleen in Jak2-V617F
MPN Mice
The Jak2-V617F mouse recapitulates many of the spleen pathologies
observed in human MPN including splenomegaly and megakaryocytic
hyperplasia. To determine the efficacy of G6 in the spleen, several pa-
rameters were measured. First, at euthanasia, spleens were immediately
removed from the mice and gross spleen weights were determined.
Figure 3A shows representative spleens from each condition and
Figure 3B shows the quantitative spleen weight–to–body weight ratios
for each group.We found that after 28 days of G6 treatment, the spleen
size, which was significantly increased in Jak2-V617F MPN mice, was
significantly reduced with G6 treatment.
Histologic sections through the spleen revealed a disorganized
splenic architecture in the Jak2-V617F MPN mice treated with vehicle
control solution and this was alleviated with G6 treatment (Figure 3C).
Examination of the sections at higher power revealed a marked mega-
karyocytic hyperplasia in the Jak2-V617F MPN mice, which was
absent in the G6-treated transgenic mice (Figure 3D). To quantitate
this hyperplasia, the average numbers of megakaryocytes per HPF were
plotted as a function of condition (Figure 3E). We found that G6 treat-
ment returned the number of megakaryocytes to normal, nontransgenic
levels. Collectively, the data in Figure 3 indicate that, in a mouse model
of Jak2-V617F–mediated myeloproliferative neoplasia, G6 provides sig-
nificant therapeutic benefit to the spleen as determined by a significantly
reduced spleen weight–to–body weight ratio, a restoration of normal
splenic architecture, and an elimination of megakaryocytic hyperplasia.
G6 Provides Therapeutic Benefit to the Bone Marrow in
Jak2-V617F MPN Mice by Alleviating Megakaryocytic
and Myeloid Hyperplasia
The ability of a drug to provide therapeutic benefit in the bone
marrow of MPN patients is critically important because this is the site
Figure 3. G6 provides therapeutic benefit to the spleen of Jak2-V617F MPN mice. (A) Representative spleens from each condition. (B)
Spleen weight–to–body weight ratios graphed as a function of treatment group. (C) Histologic sections through the spleen at low magni-
fication showing splenic architecture. (D) Histologic sections through the spleen at high magnification showingmegakaryocytic hyperplasia
in Jak2-V617F MPNmice and elimination of it with G6 treatment. (E) Number of megakaryocytes per HPF plotted as a function of treatment
group. **P < .001 and *P < .05 versus vehicle treated.
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of initiation of disease pathogenesis. In addition, this has been the point
of disappointment for current generation Jak2 inhibitors. To assess the
efficacy of G6 in the bone marrow, we first examined marrow sections.
Figure 4A shows representative histologic sections from each group. We
found that when compared to nontransgenic controls, the vehicle-treated
Jak2-V617FMPNmice had a hypercellularmarrow because of themyeloid
and megakaryocytic hyperplasia, and this corresponded with the increased
platelet counts observed in the peripheral blood (Table 1). However, G6
seemed to restore the marrow to nondiseased conditions. To confirm this
quantitatively, the average number of megakaryocytes per HPF was deter-
mined from all animals and plotted as a function of treatment group
(Figure 4B).We found that, in the Jak2-V617FMPNmice, G6 significantly
reduced the number of megakaryocytes in the marrow to nearWT levels.
It is well accepted that an altered M /E ratio is often one of the
characteristic signs of Jak2-V617F–mediated myeloproliferative neo-
plasia. To determine whether G6 could correct the abnormally high
M /E ratio in the bone marrow of the Jak2-V617F MPN mice, we
carried out a quantitative analysis of the myeloid and erythroid cells
on the marrow sections (Figure 4C ). We found that, when compared
to the WT mice, there was a robust increase in the M /E ratio in the
vehicle-treated Jak2-V617F MPN mice that was driven by myeloid
neoplasia. However, G6 treatment returned the M/E ratio to wild-type
levels. Altogether, the data in Figure 4 demonstrate that G6 has a marked
therapeutic benefit in the bone marrow. Specifically, it reduced the path-
ologic increase in megakaryocytic and myeloid hyperplasia in the marrow,
as a consequence of which, the M/E ratio was completely normalized.
G6 Provides Therapeutic Benefit to the Bone Marrow in
Jak2-V617F MPN Mice by Reducing the Pathologic
Levels of Phospho-Jak2 and Phospho-STAT5
To determine whether the therapeutic benefit observed in the marrow
with G6 treatment is a result of reduced Jak/STAT signaling, we carried
out anti–phospho-Jak2 and anti–phospho-STAT5 IHC staining of the
bone marrow sections. Figure 5A shows representative images of the
anti–phospho-Jak2 IHC at two magnifications. Qualitatively, we found
that bone marrow sections obtained from the Jak2-V617F MPN mice
Figure 4. G6 provides therapeutic benefit to the bone marrow of Jak2-V617F MPN mice by alleviating megakaryocytic and myeloid
hyperplasia. (A) Representative bone marrow sections showing the effect of G6 on megakaryocytic hyperplasia. (B) Average number
of megakaryocytes per HPF plotted as a function of treatment group. (C) M /E ratios plotted as a function of treatment group. *P < .05
and **P < .001 versus vehicle treated.
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treated with vehicle control had a robust increase in phospho-Jak2 levels
when compared to the wild-type mice. However, the phospho-Jak2
staining was reduced to wild-type levels in the Jak2-V617F MPN mice
that were treated with G6. These qualitative observations were supported
quantitatively when the numbers of anti–phospho-Jak2–stained cells
were counted and plotted as a function of treatment group (Figure 5B).
The therapeutic effect within the bone marrow was further verified
by the ability of G6 to reduce the levels of the proliferative marker,
phospho-STAT5. STAT5 is an immediate downstream target of Jak2
and is hyperphosphorylated in Jak2-V617F expressing cells [16,17].
Figure 5C shows representative bone marrow pictures of the anti–
phospho-STAT5 IHC-stained sections, and Figure 5D shows the
quantification of all sections plotted as a function of treatment group.
We similarly observed that when compared to wild-type mice, the
Jak2-V617F MPN mice that were given vehicle control solution had
pathologically high levels of phospho-STAT5. Again, however, G6
fully corrected this pathogenesis by returning the phospho-STAT5
levels to nontransgenic levels. In summary, the data in Figure 5 show that
G6 has striking therapeutic efficacy in the bone marrow. Specifically, the
Jak2-V617F MPN mice have significantly elevated levels of phospho-
Jak2 and its proliferative downstream target, phospho-STAT5. However,
G6 treatment normalizes these values to nondiseased levels.
G6 Provides Therapeutic Benefit to the Bone Marrow
in Jak2-V617F MPN Mice by Significantly Reducing
the Mutant Jak2 Burden
The greatest obstacle to current Jak2 inhibitors is the inability of
these drugs to eliminate Jak2-V617F mutant clones from the bone
marrow. To determine the efficacy of this parameter in our MPN
model, we measured the mRNA levels of both the human Jak2-
V617F mutant mRNA transcripts and endogenous mouse Jak2-WT
transcripts. We found that whereas G6 treatment significantly reduced
the levels of the mutant V617F transcripts (Figure 6A), endogenous
wild-type transcripts were only slightly reduced by G6 treatment,
and this change was not significant (Figure 6B). Furthermore, we found
that the ratio of these two parameters (i.e., the mutant burden within
the marrow) was reduced, on average, by ∼67% with G6 treatment
when compared to Jak2-V617F MPN mice that received vehicle con-
trol injections (Figure 6C). Furthermore, one third of the G6-treated
mice exhibited virtual elimination of all Jak2-V617F transcripts
from the marrow. Thus, the data in Figure 6 demonstrate that G6 sig-
nificantly reduces the burden of Jak2-V617F mutant cells from the
bone marrow in a model of Jak2-V617F–mediated myeloprolifera-
tive neoplasia.
G6 Prevents Jak2-V617F–Mediated Clonogenic Growth
Lastly, we wanted to assess whether G6 can stop the clonogenic
growth potential of Jak2-V617F transformed cells because this would
be crucial to any therapeutic possibility. For this, cells were harvested
from the bone marrow of Jak2-V617F MPN mice and cultured ex vivo
in the presence of 25 μM of G6 for 0, 12, or 24 hours. The cells were
then washed extensively to remove drug and plated in medium lacking
EPO and TPO. Five days later, the numbers of granulocyte-macrophage
colony-forming units (Figure 7A) and erythroid burst-forming units
(Figure 7B) were counted and plotted as a function of time. We found
that G6 significantly suppressed the clonogenic growth potential of
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Figure 5. G6 reduces activation of Jak2 and STAT5 in Jak2-V617F MPN mice. (A) Representative anti phospho-Jak2 IHC in bone marrow
sections from the indicated treatment groups shown at 40× and 100×. (B) Quantification of the anti–phospho-Jak2 staining plotted as a
function of treatment group. (C) Representative anti–phospho-STAT5 IHC in bone marrow sections at 40× and 100×. (D) Quantification
of the anti–phospho-STAT5 staining plotted as a function of treatment group. *P < .05 versus vehicle-treated MPN mice.
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Jak2-V617F cells in a time-dependent manner; 12 hours of drug expo-
sure resulted in ∼50% growth inhibition and 24 hours of drug expo-
sure virtually eliminated all subsequent clonogenic growth. As such,
these results indicate that brief exposures of Jak2-V617F cells to G6
prevent subsequent clonogenic growth.
Discussion
Since the discovery of the Jak2-V617F mutation in most patients
with MPN, a number of molecularly targeted Jak2 inhibitors have
been developed. However, the clinical benefits provided by these in-
hibitors so far have largely been palliative due to the inability of many
to significantly reduce malignant clones in the bone marrow. Thus,
the identification of Jak2 inhibitors that can provide significant bone
marrow efficacy is highly desirable. We present here preclinical data
demonstrating that the Jak2 inhibitor, G6, provides exceptional ther-
apeutic efficacy against Jak2-V617F–mediated myeloproliferative
neoplasia. The drug significantly reduced the Jak2-V617F allele
burden in the bone marrow. This reduction of the mutant burden
in the marrow was concomitant with the elimination of myeloid
hyperplasia, correction of the M /E ratio, normalization of the levels
of phospho-Jak2 and phospho-STAT5, and an elimination of the
Jak2-V617F–dependent clonogenic growth potential. Overall, these
results indicate that G6 is highly efficacious in the bone marrow.
In addition to providing exceptional bone marrow efficacy, G6 also
corrected virtually every pathologic MPN indicator in the peripheral
blood including the red blood cell count, hematocrit, mean corpus-
cular volume, red blood cell distribution width, hemoglobin, mean
corpuscular hemoglobin, mean corpuscular hemoglobin concentra-
tion, platelet count, mean platelet volume, platelet distribution width,
white blood cell count, neutrophil count, lymphocyte count, mono-
cyte count, and the levels of IL-6 (Table 1 and Figure 1). It also elim-
inated the EMH in the liver that was being driven by the Jak2-V617F
transgene (Figure 2). Lastly, within the spleen, G6 alleviated spleno-
megaly, significantly reduced the megakaryocytic hyperplasia, and
restored the normal architecture to this tissue (Figures 3 and 4). As
such, G6 significantly ameliorates or eliminates the pathogenesis of
nearly every indicator of the MPN phenotype. Whether these ob-
served changes result in increased animal survival is a question that
is currently being addressed experimentally.
We recently reported that G6 eliminates the Jak2-V617F mutant
burden from the bone marrow using a HEL cell xenograft model of
Jak2-V617F–mediated hyperplasia [17]. This xenograft model has
the advantage of closely replicating some aspects of human disease in-
cluding a low tumor burden in the context of the endogenous marrow
niche. Limitations of this model, however, include the overall lack of
the associated MPN phenotype including myeloid hyperplasia and an
increasedM /E ratio. Our work here is significant in that we show that
Figure 6. G6 significantly reduces mutant burden in bone marrow
of Jak2-V617F MPN mice. (A) The amount of Jak2-V617F mutant
transcripts in the bone marrow of the indicated groups. (B)
Amount of endogenous mouse Jak2-WT transcripts from the same
groups. (C) The Jak2-V617F mutant burden (the ratio of mutant
to wild type) transcripts plotted as a function of treatment group.
*P < .05.
Figure 7. G6 treatment eliminates Jak2-V617F–mediated clono-
genic growth potential. Bone marrow cells from Jak2-V617F MPN
mice were exposed to G6 for the indicated periods. Clonogenic
growth potential as assessed by the subsequent number of CFU-
GM (A) and BFU-E (B) was plotted as a function of time. *P < .05.
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G6 is also highly effective in the bone marrow using a mouse model of
Jak2-V617F–mediated human myeloproliferative neoplasia. Further-
more, G6 alleviates a number of MPN phenotypes in the peripheral
blood, spleen, and liver, which are not found in the xenograft model.
As such, the reduction/elimination of the mixed PV/ET phenotype
from these Jak2-V617F mice suggests that G6 may have therapeutic
potential for the treatment of MPN.
Potential Jak2 small-molecule inhibitor therapy is perhaps most rel-
evant to PMF and less so for PV/ET because PV/ET patients can man-
age their disease relatively well with cytoreductive therapies. However,
this is not to suggest that the results contained herein are insignificant.
To the contrary, in a recent review article, it was noted that current
limitations to any Jak2 inhibitor therapy include their potential costs
and unknown adverse effects in the long term [20]. Therefore, it was
argued that for diseases that are managed relatively well using con-
ventional therapies (i.e., PV and ET), there must be clear benefit over
the status quo if Jak2 inhibitors are to be used instead. Our preclinical
data here, in the form of repeated measures of bonemarrow efficacy in a
mouse model of PV/ET, are indicative of demonstrable efficacy over
the status quo, and hence, G6 could be relevant to PV and ET. Also,
Jak2 inhibitors are being tested in clinical studies for use in a number of
indicators including PMF, PV, ET, multiple myeloma, acute leukemia,
rheumatoid arthritis, psoriasis, and others. Therefore, indicators for
possible Jak2 therapy are both numerous and diverse. Finally, in a sep-
arate work, we have tested G6 in a mouse model of Jak2-mediated,
PMF. We found that, within the bone marrow, the drug significantly
reduced pathogenic Jak/STAT signaling, significantly reduced the Jak2
mutant burden, significantly improved theM/E ratio, and significantly
reversed the myelofibrosis (unpublished observations). As such, these
data indicate that G6 is also efficacious in PMF.
Given the causative role of Jak2 kinase in human disorders, Jak2
small molecules may have significant therapeutic potential. Accord-
ingly, within the past several years, a number of groups have developed
Jak2 inhibitors. One problem with virtually all these compounds, how-
ever, is that, although they demonstrated excellent efficacy in vitro, they
have little to no efficacy in vivo [21–24]. This critical inability to reduce
the mutant Jak2 burden in the bone marrow was the focus of a recent
and sobering review describing current obstacles and limitations in this
area of research [20]. Our work here is significant because, in addition to
having in vitro efficacy [15,16], we now show that G6 has exceptional
in vivo efficacy using a second independent model of Jak2-V617F–
mediated pathogenesis.
Perhaps the single greatest problem with current-generation Jak2
inhibitors is that they are largely palliative and not curative in any way
[14,20]. In other words, although they alleviate a number of MPN-
associated symptoms, they do not alter the burden of mutant Jak2
clones in the bone marrow and, hence, cannot change the natural pro-
gression of the disease. The efficacy observed in the bone marrow with
G6 treatment (Figures 4–6) suggests that the drug may have curative
potential. Furthermore, our observation that brief exposures of Jak2-
V617F cells to G6 completely eliminate all subsequent Jak2-V617F–
dependent clonogenic growth (Figure 7) suggests that the bone
marrow efficacy may be permanent. Studies that will determine this
experimentally are currently in progress.
G6 was identified using structure-based virtual screening [15]. It
belongs to a group of diarylethene compounds known as stilbenes.
Previously, we demonstrated that the stilbenoid core element of
G6 is essential for its therapeutic potential [16]. Stilbenes have been
reported to exhibit therapeutic efficacy in a wide variety of disease
conditions including cancer, stress, cardiovascular, and viral diseases
[25–30]. Stilbenes have also been reported to possess tyrosine kinase
inhibitory activity [29,30]. Given that stilbenes such as resveratrol
and piceatannol are naturally occurring [25–27], they are likely to have
limited adverse effects in vivo. In the current study, we did not observe
any apparent gross morphology or histologic adverse effects associated
with G6 treatment, suggesting that it may be suitable and safe for
administration to humans with MPN.
In conclusion, the results in this study demonstrate that the small-
molecule Jak2 inhibitor, G6, provides therapeutic benefit to the periph-
eral blood, liver, spleen, and, most notably, the bone marrow using a
mouse model of Jak2-V617F–mediated myeloproliferative neoplasia.
Given that the bone marrow is the predilection site for MPN disease
pathogenesis, this work is significant in that G6 may be a promising
candidate for progression into clinical trials for the treatment of MPN.
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